Reviva Pharmaceuticals Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.6M
- Price
- $0.50
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.15%
- Volume
- 57.2K
About
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Quick stats
Shares outstanding13.1M
Computed float13.1M
Float / shares100.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001742927
Websitehttps://www.revivapharma.com
AI Summary
AI-generated1/11
minorneutralother
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
Reviva Pharmaceuticals (OTCQB: RVPH) will present at the Lytham Partners Fall 2026 Investor Conference, with management's webcast scheduled for 12:30 PM ET on Tuesday, September 29, 2026, and a replay available afterward.
Founder, President and CEO Laxminarayan Bhat will lead the presentation, and management will also participate in virtual one-on-one meetings with investors throughout the event.
No new clinical, financial, or regulatory information was disclosed; the release is a routine investor-access item, with the pipeline still anchored on brilaroxazine (RP5063) and RP1208 and the planned RECOVER-2 Phase 3 trial evaluating brilaroxazine for schizophrenia.
Red flags
- Boilerplate only, but release reiterates OTCQB listing risks: limited liquidity, sporadic trading, and potential constraints on the company's ability to raise additional capital while trading on OTC Markets